To Switch or Not Switch Febuxostat: Comment on the Article by FitzGerald et al.
Chuanhui XuPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2020)
We read with great interest the recently published 2020 American College of Rheumatology guideline for the management of gout. Switching to an alternative oral urate-lowering therapy (ULT) agent is conditionally recommended for patients taking febuxostat with a history of cardiovascular disease (CVD) or a new CVD-related event. The limitation of underlying evidence based on FDA-mandated CARES trial was addressed, i.e. a high dropout rate with a majority of deaths occurring after ULT discontinuation.
Keyphrases
- cardiovascular disease
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- clinical trial
- type diabetes
- peritoneal dialysis
- study protocol
- systematic review
- randomized controlled trial
- uric acid
- rheumatoid arthritis
- single molecule
- bone marrow
- metabolic syndrome
- mesenchymal stem cells
- systemic lupus erythematosus
- patient reported outcomes
- cardiovascular events
- meta analyses